Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
Date:10/29/2009

colorectal cancer, lung cancer, ovarian cancer, and as an adjuvant therapy for liver cancer and kidney cancer.

Important Safety Considerations for Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common adverse events >/= 20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain. Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical pro
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
2. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
5. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
6. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
7. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
8. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...twonewtherapiesforNon-Hodgkin,sLymphomas(NHL),theN...mab(Azerra(TM),GlaxoSmithKline)asatherapyoptionfor...depsin(Istodax(R),GloucesterPharmaceuticals)asasug...oma(CTCL). ,, FORTWASHINGTON,Pa.,Nov.23/PRNewsw...theNationalComprehensiveCancerNetwork( NCCN )toupd...
(Date:11/23/2009)...--Reportlinker.comannouncesthatanewmarketresearchr...isposables-AWorldMarketReview ,, http://www....-A-World-Market-Review.html#utm_source=prnewswire&...,, Globalgeneralanesthesiadisposablesmarketisch...siderablerisewitnessedingeneralsurgicalprocedures,...
(Date:11/23/2009)...PRNewswire-FirstCall/-- LexiconPharmaceuticals,Inc...omitsPhase2clinicalstudywith LX1031 inpatientswith...resentedatGASTRO2009inLondonthisweek.Resultsfromth...toms,willbepresentedbyDr. PhilipM.Brown ,Lexicon,s...r25,2009at2:30pmlocaltimeatthesessionentitled,"The...
Breaking Medicine Technology:NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3Reportlinker Adds Anesthesia Disposables - A World Market Review 2Reportlinker Adds Anesthesia Disposables - A World Market Review 3Reportlinker Adds Anesthesia Disposables - A World Market Review 4Reportlinker Adds Anesthesia Disposables - A World Market Review 5Reportlinker Adds Anesthesia Disposables - A World Market Review 6Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 1Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 2Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 3Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 4Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 1Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 2One of Womens Best Kept Secrets is Now Available in the Mens Department 48145 1One of Womens Best Kept Secrets is Now Available in the Mens Department 48145 2
...to Timeline for Second Pivotal Phase 3 Trial CL-05... Advanced Life,Sciences Holdings, Inc. , today ann...ata from Trial CL-06, the first of two,pivotal Pha... and,effectiveness of cethromycin, a novel once-a-...uired pneumonia (CAP). The Company,also provided a...
..., July 2, 2007-Women with at least three sites of,...times more likely,than average women to develop br...c Cancer Center led study of women with atypical,h... 1 issue of the,Journal of Clinical Oncology., Sev...erplasia,(also called atypia) in breast tissue is ...
Other Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 2Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 3
(Date:11/23/2009)...everybody, health care professionals enjoy a pay r...inancial incentives for health care performance ma... that patient-care performance ratings for 25 medi...y following the launch of a statewide pay-for-perf...ocused on doctors, productivity. , Reporting ...
(Date:11/23/2009)...ales saw their odds drop by 63 percent with modera..., Nov. 23 (HealthDay News) -- Moderate-to-high int...s may help reduce stroke risk in older men but not...uded almost 3,300 men and women, average age 69, i.... During that time, there were 238 strokes among t...
(Date:11/23/2009)...ships doubled number of patients who reined in the...Y, Nov. 23 (HealthDay News) -- High blood pressure...orking hand-in-hand than by doctors and pharmacist...sicians work with pharmacists, medications are int... effectively," said Barry L. Carter, a professor i...
(Date:11/23/2009)...oints up weaknesses of drug approval process in Un... Nov. 23 (HealthDay News) -- Problems with the pop...k for heart attack, stroke and death, were known f...om the market in 2004, a new report says. , Co...Co., dangerous side effects were evident in 2000, ...
(Date:11/23/2009)... CENTERCITY,Minn.,Nov.23/PRNewswire/--Hazelden,the...center,todayannouncedtheleadershipteamforitsnewrec...tyinNaplesisscheduledtoopeninlateMarch2010,andwill...s,includingafullarrayoffamilyandoutpatientservices...rectorofHazelden,sfacilityinNaples,withBrendaIliff...
Breaking Medicine News(10 mins):Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 2Health News:Doctor-Pharmacist Teams Boost Blood Pressure Control 3Health News: Vioxx Problems Known Years Before Recall 2Health News: Vioxx Problems Known Years Before Recall 3Health News: Vioxx Problems Known Years Before Recall 4Health News:Hazelden Names Leadership Team for New Recovery Center in Naples, Florida 2
...fter 40, dizziness makes them 12 times more likely..., TUESDAY, May 26 (HealthDay News) -- About 69 mil...-ear dysfunction that causes dizziness and makes t...because they,ve had no previous incidents of dizzi...
... Researchers at the University of Maryland School...treating rheumatoid arthritis reduces severe illne...rus. Their findings suggest that tempering the res...The scientists report in the June 1 edition of Th...
... PROVIDENCE, RI A new study published online in ...at strict maternal control over eating habits suc...oaxing them to eat certain foods during early chi... weight. , "Our findings suggest that controlling...
... Pediatric dermatologist-researcher Alfred Lane, M...e a sign of ultraviolet radiation damage, warns La...D, knows that kids love summer and kids love sun. ...-UPcx , , (Photo: http://www.newscom.com/cgi-bi...
... Market Scope has announc...itions of two of its three comprehensive reports o...et Scope, this is a very exciting time in the reti...untreatable. Investigational devices are promising...
... Pre-opening event raises more than $1,000 for Fir..., May 26 LongHorn Steakhouse today announced the ...reet in Homestead, Fla. The Homestead location is... the restaurant recently hosted a Friends and Fami...
Other Medicine News:Health News:Inner Ear Dysfunction Puts Older Adults at Risk of Falls 2Health News:Arthritis drug might prove effective in fighting the flu, study suggests 2Health News:Arthritis drug might prove effective in fighting the flu, study suggests 3Health News:Strict maternal feeding practices not linked to child weight gain 2Health News:There's No Such Thing as a Good Tan 2Health News:There's No Such Thing as a Good Tan 3Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 3Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 4Health News:LongHorn Steakhouse Brings the Spirit of the West to Homestead 2
...xperience the finest surgical-quality loupes avail...andard for innovative optical design, combining su...livering optimum performance with maximum comfort,...al professionals worldwide. All SheerVision loupes...
...xperience the finest surgical-quality loupes avail...andard for innovative optical design, combining su...ivering optimum performance with maximum comfort, ...l professionals worldwide. Make both a professiona...
...hese award-winning surgical loupes from SheerVisio...resolution optics combined with light-weight comfo...s weight as little as 1.5 ounces when included wit...in either a flip-up or through-the-lens (TTL) desi...
...heerVision is now the first manufacturer to offer ...he wearer. These next generation loupes feature ex...tra-lightweight design, and are multi-coated lens ...With SheerVision's proprietary SureFit system - yo...
Medicine Products: